Bupropion Sustained released versus Placebo for seasonal affective Disorder
<p><strong>Background</strong>: The majority of seasonal affective disorder (SAD) studies have evaluated the use of light or selective serotonin reuptake inhibitors (SSRI). The purpose of the present study was to evaluate bupropion sustained-released (SR), a non-SSRI antidepre...
Saved in:
Main Authors: | , , |
---|---|
Format: | Book |
Published: |
Archives of Depression and Anxiety - Peertechz Publications,
2017-05-26.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | <p><strong>Background</strong>: The majority of seasonal affective disorder (SAD) studies have evaluated the use of light or selective serotonin reuptake inhibitors (SSRI). The purpose of the present study was to evaluate bupropion sustained-released (SR), a non-SSRI antidepressant, for the treatment of SAD.</p><p><strong>Method</strong>: Forty-one adults meeting DSM IV criteria for SAD were recruited into a six-week, randomized, double-blind, placebo-controlled trial. Participants started on bupropion SR 150 mg QD (or equivalent placebo pills) and titrated up to 200 mg BID if tolerated by week 4. Participants were evaluated weekly with SIGH-SAD and self-reported Kellner Symptom Questionnaire (SQ). Mixed effects growth models and receiver operating characteristic (ROC) analyses were used to compare treatments.</p><p><strong>Results </strong>: Analysis was done on the 36 participants who completed at least 2 weeks of treatment, as per protocol. Thirty-four participants completed the entire protocol; two participants receiving placebo dropped out during weeks 3 and 5. Sixteen participants (7 male, 9 female, 46.5 + 9.6 years, mean+SD) received bupropion SR and 20 participants (8 males, 12 females, 48.2+8.8 years) received placebo. Participants receiving bupropion SR had a more rapid reduction in atypical SIGH-SAD depressive symptoms and lower depression scores across time on the SQ. ROC analyses revealed that positive effects of bupropion SR on total SIGH-SAD scores were more evident in males than females. Bupropion SR was well tolerated. </p><p><strong>Conclusion </strong>: Bupropion SR may be beneficial for the treatment of SAD, but larger randomized placebo- controlled studies are warranted</p> |
---|---|
DOI: | 10.17352/2455-5460.000016 |